{
  "docId": "019de075-a749-75ad-9c96-b2ef130e2f41",
  "docSlug": "810e8355c3b124b062a449d6b3848ba9",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 9,
  "pageCount": 49,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 7,
  "notes": "Includes extensive disclaimer text regarding cross-trial comparison limitations.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/9",
  "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41",
  "deckJsonHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41.json",
  "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-9",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.5,
        "x": 0.15,
        "y": 0.2
      },
      "kind": "chart",
      "text": "Overall Response Rate in relapsed/refractory AL Amyloidosis",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3c45d1f4-5ecc-4a00-83d7-650b586f443b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.88
      },
      "kind": "disclaimer",
      "text": "Birtamimab Source: Gertz MA et al... Differences exist between trial designs and subject characteristics, and caution should be exercised when comparing data across studies.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3858082c-44c3-4178-854d-f3c2a2568463",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.25,
        "x": 0.7,
        "y": 0.2
      },
      "kind": "list",
      "text": "NXC-201 Only CAR-T in AL Amyloidosis; NXC-201 100% Overall Response Rate; Organ responses exceed purpose-designed CAEL-101 and Birtamimab combinations; Zero Neurotoxicity of any grade",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3de1217b-dc69-426d-a6c3-b5f11a2e3897",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.8,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "NXC-201 Clinical Results Demonstrate Potential for Best-in-Class Efficacy & Safety in relapsed/refractory AL (light chain) Amyloidosis, a $6 billion market by 2025",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5c7ab7bc-8cb7-4dbf-b421-8824782972d4",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "2x2 matrix",
      "slug": "matrix-2x2",
      "agent": null,
      "layer": "slide",
      "matchId": "881665c5-7062-4435-8c41-2961f056a6df",
      "evidence": "Although not explicitly visible, the comparison of clinical data across different treatments might imply a 2x2 matrix or similar comparison framework.",
      "confidence": 0.5
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 21,
      "from": 8,
      "beatId": "a874b208-4408-43df-9863-8c8c163ed01d",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "Presentation of clinical data and competitive analysis for NXC-201",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 21,
      "from": 7,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "6ea19383-9ed5-41d1-ac2b-d7d037efe2d8",
      "evidence": "Discussion of neurotoxicity associated with existing BCMA CAR-T therapies",
      "position": 0,
      "objective": "Highlighting the need for improved therapies",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}